報酬
リスク分析
Agios Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$44.87 |
| 52週高値 | US$53.29 |
| 52週安値 | US$20.40 |
| ベータ | 0.75 |
| 11ヶ月の変化 | 8.58% |
| 3ヶ月変化 | 5.30% |
| 1年変化 | 100.13% |
| 33年間の変化 | -0.82% |
| 5年間の変化 | 38.36% |
| IPOからの変化 | 43.45% |
最新ニュース
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Recent updates
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21株主還元
| AGIO | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -2.6% | -0.7% | -1.6% |
| 1Y | 100.1% | 19.8% | 30.8% |
業界別リターン: AGIO exceeded the US Biotechs industry which returned 19.8% over the past year.
リターン対市場: AGIO exceeded the US Market which returned 30.8% over the past year.
価格変動
| AGIO volatility | |
|---|---|
| AGIO Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: AGIO has not had significant price volatility in the past 3 months compared to the US market.
時間の経過による変動: AGIO's weekly volatility (5%) has been stable over the past year.
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2007 | 385 | Brian Goff | www.agios.com |
バイオ医薬品会社であるアギオス・ファーマシューティカルズ・インクは、米国で細胞代謝分野の医薬品を創製・開発している。同社の主力製品には、溶血性貧血の治療薬として、野生型および変異型ピルビン酸キナーゼ（PK）酵素の活性化剤であるPYRUKYND（mitapivat）がある。同社は、低リスクの骨髄異形成症候群および溶血性貧血の治療薬としてPK活性化剤AG-946、フェニルケトン尿症の治療薬としてフェニルアラニン水酸化酵素安定化剤AG-181を開発している。前臨床段階の製品は、希少な血液疾患である真性多血症の治療用siRNAである。アジオス・ファーマシューティカルズ・インクは2007年に設立され、マサチューセッツ州ケンブリッジに本社を置いている。
Agios Pharmaceuticals, Inc. 基礎のまとめ
| AGIO 基礎統計学 | |
|---|---|
| 時価総額 | US$2.56b |
| 収益（TTM） | US$674.31m |
| 売上高(TTM) | US$32.87m |
3.8x
PER（株価収益率77.8x
P/SレシオAGIO は割高か？
公正価値と評価分析を参照収益と収入
| AGIO 損益計算書（TTM） | |
|---|---|
| 収益 | US$32.87m |
| 売上原価 | US$299.46m |
| 売上総利益 | -US$266.58m |
| その他の費用 | -US$940.89m |
| 収益 | US$674.31m |
直近の収益報告
Sep 30, 2024
次回決算日
該当なし
| 一株当たり利益（EPS） | 11.82 |
| グロス・マージン | -811.00% |
| 純利益率 | 2,051.38% |
| 有利子負債／自己資本比率 | 0% |
AGIO の長期的なパフォーマンスは？
過去の実績と比較を見る